haic
Showing 1 - 23 of 23
Carcinoma, Intrahepatic Cholangiocarcinoma, Gallbladder Cancer Trial (HAIC, Surufatinib, Tislelizumab)
Not yet recruiting
- Carcinoma
- +7 more
- HAIC
- +2 more
- (no location specified)
Nov 12, 2023
Unresectable Hepatocellular Carcinoma Trial in Nanchang (D-TACE, HAIC, Lenvatinib)
Recruiting
- Unresectable Hepatocellular Carcinoma
- D-TACE
- +3 more
-
Nanchang, Jiangxi, ChinaThe Second Affiliated Hospital of Nanchang University
Oct 14, 2022
Macrotrabecular Massive Hepatocellular Carcinoma Trial in Wuhan (HAIC, Camrelizumab plus Apatinib)
Recruiting
- Macrotrabecular Massive Hepatocellular Carcinoma
- HAIC
- Camrelizumab plus Apatinib
-
Wuhan, Hubei, ChinaHepatic Surgery Center, Tongji Hospital, Tongji Medical College,
May 1, 2023
Hepatocellular Carcinoma Trial in Tianjin (HAIC, Sintilimab, Lenvatinib)
Not yet recruiting
- Hepatocellular Carcinoma
- HAIC
- +2 more
-
Tianjin, Tianjin, ChinaTianjin Medical University Cancer Institute & Hospital
Nov 10, 2022
Hepatocellular Carcinoma Trial in Wuhan (HAIC, Sintilimab, Bevacizumab Biosimilar IBI305)
Recruiting
- Hepatocellular Carcinoma
- HAIC
- +2 more
-
Wuhan, Hubei, ChinaUnion Hospital affiliated to Tongji Medical College of Huazhong
Nov 8, 2022
Hepatocellular Carcinoma Trial in Guangzhou (HAIC, Zoledronic acid)
Recruiting
- Hepatocellular Carcinoma
- HAIC
- Zoledronic acid
-
Guangzhou, Guangdong, ChinaCancer Center Sun Yat-sen University
May 10, 2023
Unresectable Hepatocellular Carcinoma Trial in Guangzhou (dTACE-HAIC, HAIC, dTACE-HAIC protocol)
Recruiting
- Unresectable Hepatocellular Carcinoma
- dTACE-HAIC
- +3 more
-
Guangzhou, Guangdong, Chinathe Second Affiliated Hospital of Guangzhou Medical University
Feb 22, 2022
Colorectal Cancer Trial in Shanghai (HAIC, Fruquintinib, Tislelizumab)
Recruiting
- Colorectal Cancer
- HAIC
- +5 more
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Aug 15, 2022
Colorectal Liver Metastases Trial in Beijing (Tislelizumab, Regorafenib, HAIC)
Recruiting
- Colorectal Liver Metastases
- Tislelizumab
- +2 more
-
Beijing, Beijing, China
- +1 more
May 25, 2023
Biliary Tract Adenocarcinoma Trial in Shanghai (HAIC, Gemcitabine, Oxaliplatin)
Enrolling by invitation
- Biliary Tract Adenocarcinoma
- HAIC
- +4 more
-
Shanghai, ChinaFudan University Shanghai Cancer Center
May 27, 2022
Hepatocellular Carcinoma Trial in Foshan, Guangzhou (HAIC, FOLFOX 2d, FOLFOX 1d)
Recruiting
- Hepatocellular Carcinoma
- HAIC
- +2 more
-
Foshan, Guangdong, China
- +2 more
Jul 26, 2022
Hepatocellular Carcinoma Trial in Tianjin (HAIC, Sintilimab, Bevacizumab Biosimilar)
Recruiting
- Hepatocellular Carcinoma
- HAIC
- +2 more
-
Tianjin, Tianjin, ChinaTianjin Medical University Cancer Institute & Hospital
Jan 16, 2022
Potentially Resection, Hepatocellular Carcinoma Trial in Guangzhou (TACE-HAIC, HAIC)
Recruiting
- Potentially Resection
- Hepatocellular Carcinoma
- TACE-HAIC
- HAIC
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Sep 20, 2021
Unresectable Hepatocellular Carcinoma Trial in Beijing (Camrelizumab, HAIC, TKI)
Recruiting
- Unresectable Hepatocellular Carcinoma
- Camrelizumab
- +2 more
-
Beijing, Beijing, ChinaCancer Institute and Hospital, Chinese Academy of Medical Scienc
Nov 22, 2021
Hepatocellular Carcinoma Trial in Beijing (HAIC, TACE, FOLFOX)
Recruiting
- Hepatocellular Carcinoma
- HAIC
- +4 more
-
Beijing, Beijing, ChinaPeking University Cancer Hospital
Jan 10, 2022
Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for
Recruiting
- Hepatocellular Carcinoma Non-resectable
- HAIC
- +8 more
-
Quanzhou, Fujian, China
- +1 more
Jan 26, 2023
Hepatocellular Carcinoma Trial in Tianjin (HAIC, Adebrelimab, Bevacizumab)
Not yet recruiting
- Hepatocellular Carcinoma
- HAIC
- +2 more
-
Tianjin, Tianjin, ChinaTianjin Cancer Hospital Airport Hospital
Jul 27, 2023
Hepatocellular Carcinoma Trial in Guangzhou (HAIC, Sorafenib)
Completed
- Hepatocellular Carcinoma
- HAIC
- Sorafenib
-
Guangzhou, Guangdong, ChinaCancer Center Sun Yat-sen University
Nov 16, 2021
Hepatocellular Carcinoma, Portal Vein Thrombosis Trial in Beijing (HAIC, Lenvatinib 1, Camrelizumab 1)
Recruiting
- Hepatocellular Carcinoma
- Portal Vein Thrombosis
- HAIC
- +4 more
-
Beijing, Beijing, ChinaPeking Univerisity Cancer Hospital
Jan 10, 2022
HepatoCellular Carcinoma, Portal Vein Thrombosis Trial in Beijing (HAIC, Sorafenib)
Completed
- HepatoCellular Carcinoma
- Portal Vein Thrombosis
- HAIC
- Sorafenib
-
Beijing, Beijing, ChinaPeking University Cancer Hospital
Oct 8, 2021
Hepatocellular Carcinoma Trial in Guangzhou, Kaiping (HAIC, PD-1 antibody, Sorafenib)
Withdrawn
- Hepatocellular Carcinoma
- HAIC
- +2 more
-
Guangzhou, Guangdong, China
- +2 more
May 2, 2019